PETACH TIKVA, Israel--(BUSINESS WIRE)--April 3, 2006--Can-Fite BioPharma (TASE:CFBI), a world leader in development of drugs that are agonists of the A3 adenosine receptor (A3AR agonists), announced today on the signing of a memorandum of understanding (MOU) with a Japanese Company for out-licensing of rights for use of CF101 for treatment of inflammatory diseases in Japan.
